Rise in cases of drug abuse is fueling the drugs of abuse testing market size. Urine testing is the most common test as it is non-invasive, quick, and able to qualitatively detect a wide range of drugs.
Approval and launch of new tests is driving the drugs of abuse testing market trajectory. LC-tandem-MS are becoming a new gold standard for confirmatory substance abuse screening with selected ion monitoring (SIM) for immunoassay confirmation, targeted screening, and quantification.
Major players operating in the drugs of abuse testing market landscape are reducing product costs to provide greater access to high-quality drug abuse tests for people living in the least developed countries where the need is most urgent.
They are also launching portable devices for on-the-go drugs screening of substance abuse.
Drugs of abuse testing detects the presence or absence of commonly abused medicines. Drugs that are abused can be classified into natural drugs, semi-synthetic drugs, and synthetic drugs.
Natural drugs are sourced from one of the following three plants - opium poppy (Papaver somniferous), cannabis, and coca. Alcohol, cocaine, opioids, inhalants, marijuana, 3, 4-methylenedioxy-N-methamphetamine (MDMA), methamphetamine, nicotine, psychedelics, dissociative drugs, and GHB & Rohypnol are the most common drugs of abuse.
Drugs of abuse testing looks for the presence of small molecules (metabolites) released during the breakdown of any of these ingested medicines. This testing is widely used in clinical and forensic settings. Urine is the preferred type of specimen for drugs of abuse testing.
However, saliva, sweat, hair, and meconium are emerging types of specimens. Drugs of abuse testing helps confirm the recent use of an abused drug. It plays a major role in diagnosis, treatment, and addiction monitoring.
| Attribute | Detail |
|---|---|
| Drivers |
|
The use of illegal drugs has been a long-standing problem in many countries. Excess consumption or dependency on illicit drugs can impact overall health, mental well-being, and in many cases, the well-being of others.
According to the UNODC World Drug Report 2022, around 284 million people aged 15-64 used drugs worldwide in 2020, a 26% increase over the previous decade.
In recent years, several countries across the globe are experiencing increase in cases and death rates due to the abuse of prescription drugs or nonmedical utilization of prescription drugs. Drug use is high among the young population.
Among people aged 12 or older in 2022, 59.8% (or 168.7 million people) used tobacco products, vaped nicotine, used alcohol, or used an illicit drug in the past month, including 48.7% (or 137.4 million people) who drank alcohol, 18.1% (or 50.9 million people) who used tobacco products, 8.3% (or 23.5 million people) who vaped nicotine, and 16.5% (or 46.6 million people) who used an illicit drug, as per the 2022 National Survey on Drug Use and Health (NSDUH) report.
Thus, surge in cases of drug abuse is propelling the drugs of abuse testing market value.
Youth in many countries are using several pain relievers, such as OxyContin and Vicodin, which are considered abused prescription drugs.
Moreover, there is a notable increase in comorbid illnesses among the older population due to incorrect prescriptions and addiction to prescription drugs. Hence, continuous increase in drug abuse is driving the drugs of abuse testing market development.
Opioid abuse, misuse, and addiction is one of the most profound public health crises in many countries. This has promoted the approval and launch of new drug abuse tests.
In October 2023, The U.S. Food and Drug Administration (FDA) cleared for marketing Alltest Fentanyl Urine Test Cassette, the first over-the-counter test to detect fentanyl in urine.
The five-minute test provides only preliminary results and includes a pre-addressed mailing box for shipping samples to the manufacturer’s laboratory for confirmation testing using an alternative chemical method.
Implementation of stringent anti-doping regulations is expected to spur the drugs of abuse testing market growth in the near future. In 2023, the U.S. Navy announced to start random drug testing of its special operations forces amid widespread concerns over the use of performance-enhancing drugs.
Surge in cases of doping in competitive sports is also driving the drugs of abuse testing market revenue.
In March 2023, the Athletics Integrity Unit (AIU) announced that athletes from Brazil, Ecuador, Peru, and Portugal will face more stringent out-of-competition (OOC) testing to be eligible for the Paris Olympics as their national testing programs are not sufficient.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest drugs of abuse testing market trends, North America held largest share in 2022. Rise in consumption of illicit drugs is fueling the market dynamics of the region.
Nearly 49 million people in the U.S. ages 12 and older - more than 1 in 6 - had a substance use disorder in 2022, according to survey data released by the U.S. Department of Health and Human Services.
Approval and launch of oral fluid testing is augmenting the drugs of abuse testing market share in North America. In May 2023, the U.S. Department of Transportation (DOT) published a final rule amending its regulated industry drug testing program to allow for oral fluid testing.
Oral fluid testing offers several advantages over other types of tests such as urine or hair follicle tests. Oral fluid collection is directly observed by a laboratory technician, making the sample less susceptible to adulteration or tampering.
The global drugs of abuse testing market is highly fragmented due to the presence of several international players. This scenario represents an intense competition in the market.
Thus, major drugs of abuse testing companies are offering liquid chromatograph tandem mass spectrometer (LC/MS/MS) technology products to provide high sensitivity and reliable results to healthcare providers and employers.
Laboratory Corporation of America Holdings, Danaher Corporation, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Drägerwerk AG & Co. KGaA, Shimadzu Corporation, and CareHealth America Corp. are key players operating in the drugs of abuse testing industry.
Each of these companies has been profiled in the drugs of abuse testing market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 5.9 Bn |
| Market Forecast (Value) in 2031 | US$ 18.7 Bn |
| Growth Rate (CAGR) | 13.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 5.9 Bn in 2022
It is anticipated to advance at a CAGR of 13.5% from 2023 to 2031
Rise in cases of drug abuse and approval and launch of new tests
North America was the most lucrative region in 2022
Laboratory Corporation of America Holdings, Danaher Corporation, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Drägerwerk AG & Co. KGaA, Shimadzu Corporation, and CareHealth America Corp.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drugs of Abuse Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drugs of Abuse Testing Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drugs of Abuse Testing Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017-2031
6.3.1. Analyzers
6.3.1.1. Immunoassays Analyzers
6.3.1.2. Chromatographic Devices
6.3.1.3. Breath Analyzers
6.3.2. Rapid Testing Devices
6.3.2.1. Urine Testing Devices
6.3.2.2. Oral Fluid Testing Devices
6.3.3. Consumables
6.3.3.1. Fluid Collection Devices
6.3.3.2. Others
6.4. Market Attractiveness, by Product Type
7. Global Drugs of Abuse Testing Market Analysis and Forecast, by Sample Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Sample Type, 2017-2031
7.3.1. Saliva
7.3.2. Breath
7.3.3. Urine
7.3.4. Blood
7.3.5. Hair & Sweat
7.4. Market Attractiveness, by Sample Type
8. Global Drugs of Abuse Testing Market Analysis and Forecast, by Testing Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Testing Type, 2017-2031
8.3.1. Pain Management Testing
8.3.2. Criminal Justice Testing
8.3.3. Workplace Screening
8.4. Market Attractiveness, by Testing Type
9. Global Drugs of Abuse Testing Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostics Laboratories
9.3.3. On-the-spot Testing
9.3.4. Forensic Laboratories
9.4. Market Attractiveness, by End-user
10. Global Drugs of Abuse Testing Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Drugs of Abuse Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017-2031
11.2.1. Analyzers
11.2.1.1. Immunoassays Analyzers
11.2.1.2. Chromatographic Devices
11.2.1.3. Breath Analyzers
11.2.2. Rapid Testing Devices
11.2.2.1. Urine Testing Devices
11.2.2.2. Oral Fluid Testing Devices
11.2.3. Consumables
11.2.3.1. Fluid Collection Devices
11.2.3.2. Others
11.3. Market Attractiveness, by Product Type
11.4. Market Value Forecast, by Sample Type, 2017-2031
11.4.1. Saliva
11.4.2. Breath
11.4.3. Urine
11.4.4. Blood
11.4.5. Hair & Sweat
11.5. Market Attractiveness, by Sample Type
11.6. Market Value Forecast, by Testing Type, 2017-2031
11.6.1. Pain Management Testing
11.6.2. Criminal Justice Testing
11.6.3. Workplace Screening
11.7. Market Attractiveness, by Testing Type
11.8. Market Value Forecast, by End-user, 2017-2031
11.8.1. Hospitals
11.8.2. Diagnostics Laboratories
11.8.3. On-the-spot Testing
11.8.4. Forensic Laboratories
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Product Type
11.11.2. By Sample Type
11.11.3. By Testing Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Drugs of Abuse Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017-2031
12.2.1. Analyzers
12.2.1.1. Immunoassays Analyzers
12.2.1.2. Chromatographic Devices
12.2.1.3. Breath Analyzers
12.2.2. Rapid Testing Devices
12.2.2.1. Urine Testing Devices
12.2.2.2. Oral Fluid Testing Devices
12.2.3. Consumables
12.2.3.1. Fluid Collection Devices
12.2.3.2. Others
12.3. Market Attractiveness, by Product Type
12.4. Market Value Forecast, by Sample Type, 2017-2031
12.4.1. Saliva
12.4.2. Breath
12.4.3. Urine
12.4.4. Blood
12.4.5. Hair & Sweat
12.5. Market Attractiveness, by Sample Type
12.6. Market Value Forecast, by Testing Type, 2017-2031
12.6.1. Pain Management Testing
12.6.2. Criminal Justice Testing
12.6.3. Workplace Screening
12.7. Market Attractiveness, by Testing Type
12.8. Market Value Forecast, by End-user, 2017-2031
12.8.1. Hospitals
12.8.2. Diagnostics Laboratories
12.8.3. On-the-spot Testing
12.8.4. Forensic Laboratories
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Product Type
12.11.2. By Sample Type
12.11.3. By Testing Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Drugs of Abuse Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017-2031
13.2.1. Analyzers
13.2.1.1. Immunoassays Analyzers
13.2.1.2. Chromatographic Devices
13.2.1.3. Breath Analyzers
13.2.2. Rapid Testing Devices
13.2.2.1. Urine Testing Devices
13.2.2.2. Oral Fluid Testing Devices
13.2.3. Consumables
13.2.3.1. Fluid Collection Devices
13.2.3.2. Others
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Sample Type, 2017-2031
13.4.1. Saliva
13.4.2. Breath
13.4.3. Urine
13.4.4. Blood
13.4.5. Hair & Sweat
13.5. Market Attractiveness, by Sample Type
13.6. Market Value Forecast, by Testing Type, 2017-2031
13.6.1. Pain Management Testing
13.6.2. Criminal Justice Testing
13.6.3. Workplace Screening
13.7. Market Attractiveness, by Testing Type
13.8. Market Value Forecast, by End-user, 2017-2031
13.8.1. Hospitals
13.8.2. Diagnostics Laboratories
13.8.3. On-the-spot Testing
13.8.4. Forensic Laboratories
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Product Type
13.11.2. By Sample Type
13.11.3. By Testing Type
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Drugs of Abuse Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017-2031
14.2.1. Analyzers
14.2.1.1. Immunoassays Analyzers
14.2.1.2. Chromatographic Devices
14.2.1.3. Breath Analyzers
14.2.2. Rapid Testing Devices
14.2.2.1. Urine Testing Devices
14.2.2.2. Oral Fluid Testing Devices
14.2.3. Consumables
14.2.3.1. Fluid Collection Devices
14.2.3.2. Others
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Sample Type, 2017-2031
14.4.1. Saliva
14.4.2. Breath
14.4.3. Urine
14.4.4. Blood
14.4.5. Hair & Sweat
14.5. Market Attractiveness, by Sample Type
14.6. Market Value Forecast, by Testing Type, 2017-2031
14.6.1. Pain Management Testing
14.6.2. Criminal Justice Testing
14.6.3. Workplace Screening
14.7. Market Attractiveness, by Testing Type
14.8. Market Value Forecast, by End-user, 2017-2031
14.8.1. Hospitals
14.8.2. Diagnostics Laboratories
14.8.3. On-the-spot Testing
14.8.4. Forensic Laboratories
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Product Type
14.11.2. By Sample Type
14.11.3. By Testing Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Drugs of Abuse Testing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017-2031
15.2.1. Analyzers
15.2.1.1. Immunoassays Analyzers
15.2.1.2. Chromatographic Devices
15.2.1.3. Breath Analyzers
15.2.2. Rapid Testing Devices
15.2.2.1. Urine Testing Devices
15.2.2.2. Oral Fluid Testing Devices
15.2.3. Consumables
15.2.3.1. Fluid Collection Devices
15.2.3.2. Others
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Sample Type, 2017-2031
15.4.1. Saliva
15.4.2. Breath
15.4.3. Urine
15.4.4. Blood
15.4.5. Hair & Sweat
15.5. Market Attractiveness, by Sample Type
15.6. Market Value Forecast, by Testing Type, 2017-2031
15.6.1. Pain Management Testing
15.6.2. Criminal Justice Testing
15.6.3. Workplace Screening
15.7. Market Attractiveness, by Testing Type
15.8. Market Value Forecast, by End-user, 2017-2031
15.8.1. Hospitals
15.8.2. Diagnostics Laboratories
15.8.3. On-the-spot Testing
15.8.4. Forensic Laboratories
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Product Type
15.11.2. By Sample Type
15.11.3. By Testing Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Danaher Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Abbott
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Siemens Healthineers
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Laboratory Corporation of America Holdings
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Drägerwerk AG & Co. KGaA
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Shimadzu Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. CareHealth America Corp.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Thermo Fisher Scientific, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
List of Tables
Table 01: Global Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 02: Global Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Sample Type, 2017-2031
Table 03: Global Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 04: Global Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Testing Type, 2017-2031
Table 05: Global Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 08: North America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Sample Type, 2017-2031
Table 09: North America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Testing Type, 2017-2031
Table 10: North America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 13: Europe Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Sample Type, 2017-2031
Table 14: Europe Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Testing Type, 2017-2031
Table 15: Europe Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 18: Asia Pacific Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Sample Type, 2017-2031
Table 19: Asia Pacific Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Testing Type, 2017-2031
Table 20: Asia Pacific Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 23: Latin America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Sample Type, 2017-2031
Table 24: Latin America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Testing Type, 2017-2031
Table 25: Latin America Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 28: Middle East & Africa Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Sample Type, 2017-2031
Table 29: Middle East & Africa Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by Testing Type, 2017-2031
Table 30: Middle East & Africa Drugs of Abuse Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Drugs of Abuse Testing Market Size (US$ Mn), by Region, 2022 and 2031
Figure 02: Global Drugs of Abuse Testing Market Revenue (US$ Mn), by Product Type, 2022
Figure 03: Global Drugs of Abuse Testing Market Value Share, by Product Type, 2022
Figure 04: Global Drugs of Abuse Testing Market Revenue (US$ Mn), by Sample Type, 2022
Figure 05: Global Drugs of Abuse Testing Market Value Share, by Sample Type, 2022
Figure 06: Global Drugs of Abuse Testing Market Revenue (US$ Mn), by Testing Type, 2022
Figure 07: Global Drugs of Abuse Testing Market Value Share, by Testing Type, 2022
Figure 08: Global Drugs of Abuse Testing Market Revenue (US$ Mn), by End-user, 2022
Figure 09: Global Drugs of Abuse Testing Market Value Share, by End-user, 2022
Figure 10: Global Drugs of Abuse Testing Market Value Share, by Region, 2022
Figure 11: Global Drugs of Abuse Testing Market Value (US$ Mn) Forecast, 2017-2031
Figure 12: Global Drugs of Abuse Testing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 13: Global Drugs of Abuse Testing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 14: Global Drugs of Abuse Testing Market Value Share Analysis, by Sample Type, 2022 and 2031
Figure 15: Global Drugs of Abuse Testing Market Attractiveness Analysis, by Sample Type, 2023-2031
Figure 16: Global Drugs of Abuse Testing Market Value Share Analysis, by Testing Type, 2022 and 2031
Figure 17: Global Drugs of Abuse Testing Market Attractiveness Analysis, by Testing Type, 2023-2031
Figure 18: Global Drugs of Abuse Testing Market Revenue (US$ Mn), by End-user, 2022
Figure 19: Global Drugs of Abuse Testing Market Value Share, by End-user, 2022
Figure 20: Global Drugs of Abuse Testing Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Drugs of Abuse Testing Market Attractiveness Analysis, by Region, 2023-2031
Figure 22: North America Drugs of Abuse Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 23: North America Drugs of Abuse Testing Market Attractiveness Analysis, by Country, 2023-2031
Figure 24: North America Drugs of Abuse Testing Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Drugs of Abuse Testing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 26: North America Drugs of Abuse Testing Market Value Share Analysis, by Sample Type, 2022 and 2031
Figure 27: North America Drugs of Abuse Testing Market Value Share Analysis, by Testing Type, 2022 and 2031
Figure 28: North America Drugs of Abuse Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 29: North America Drugs of Abuse Testing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 30: North America Drugs of Abuse Testing Market Attractiveness Analysis, by Sample Type, 2023-2031
Figure 31: North America Drugs of Abuse Testing Market Attractiveness Analysis, by Testing Type, 2023-2031
Figure 32: North America Drugs of Abuse Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 33: Europe Drugs of Abuse Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 34: Europe Drugs of Abuse Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 35: Europe Drugs of Abuse Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Drugs of Abuse Testing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 37: Europe Drugs of Abuse Testing Market Value Share Analysis, by Sample Type, 2022 and 2031
Figure 38: Europe Drugs of Abuse Testing Market Value Share Analysis, by Testing Type, 2022 and 2031
Figure 39: Europe Drugs of Abuse Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Europe Drugs of Abuse Testing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 41: Europe Drugs of Abuse Testing Market Attractiveness Analysis, by Sample Type, 2023-2031
Figure 42: Europe Drugs of Abuse Testing Market Attractiveness Analysis, by Testing Type, 2023-2031
Figure 43: Europe Drugs of Abuse Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 44: Asia Pacific Drugs of Abuse Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 45: Asia Pacific Drugs of Abuse Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46: Asia Pacific Drugs of Abuse Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Drugs of Abuse Testing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 48: Asia Pacific Drugs of Abuse Testing Market Value Share Analysis, by Sample Type, 2022 and 2031
Figure 49: Asia Pacific Drugs of Abuse Testing Market Value Share Analysis, by Testing Type, 2022 and 2031
Figure 50: Asia Pacific Drugs of Abuse Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Asia Pacific Drugs of Abuse Testing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 52: Asia Pacific Drugs of Abuse Testing Market Attractiveness Analysis, by Sample Type, 2023-2031
Figure 53: Asia Pacific Drugs of Abuse Testing Market Attractiveness Analysis, by Testing Type, 2023-2031
Figure 54: Asia Pacific Drugs of Abuse Testing Market Attractiveness Analysis, by End-user, 2022-2031
Figure 55: Latin America Drugs of Abuse Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 56: Latin America Drugs of Abuse Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 57: Latin America Drugs of Abuse Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Latin America Drugs of Abuse Testing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 59: Latin America Drugs of Abuse Testing Market Value Share Analysis, by Sample Type, 2022 and 2031
Figure 60: Latin America Drugs of Abuse Testing Market Value Share Analysis, by Testing Type, 2022 and 2031
Figure 61: Latin America Drugs of Abuse Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 62: Latin America Drugs of Abuse Testing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 63: Latin America Drugs of Abuse Testing Market Attractiveness Analysis, by Sample Type, 2023-2031
Figure 64: Latin America Drugs of Abuse Testing Market Attractiveness Analysis, by Testing Type, 2023-2031
Figure 65: Latin America Drugs of Abuse Testing Market Attractiveness Analysis, by End-user, 2023-2031
Figure 66: Middle East & Africa Drugs of Abuse Testing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 67: Middle East & Africa Drugs of Abuse Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 68: Middle East & Africa Drugs of Abuse Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 69: Middle East & Africa Drugs of Abuse Testing Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 70: Middle East & Africa Drugs of Abuse Testing Market Value Share Analysis, by Sample Type, 2022 and 2031
Figure 71: Middle East & Africa Drugs of Abuse Testing Market Value Share Analysis, by Testing Type, 2022 and 2031
Figure 72: Middle East & Africa Drugs of Abuse Testing Market Value Share Analysis, by End-user, 2022 and 2031
Figure 73: Middle East & Africa Drugs of Abuse Testing Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 74: Middle East & Africa Drugs of Abuse Testing Market Attractiveness Analysis, by Sample Type, 2023-2031
Figure 75: Middle East & Africa Drugs of Abuse Testing Market Attractiveness Analysis, by Testing Type, 2023-2031
Figure 76: Middle East & Africa Drugs of Abuse Testing Market Attractiveness Analysis, by End-user, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drugs of Abuse Testing Market
*86 figures and 60 tables includes